|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Glucagon-like peptide-1 receptor agonists (GLP-1RA) are drugs used in type 2 diabetes that have a low risk of hypoglycemia and have been shown to exert neuroprotective effects.
|
31518433 |
2019 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hypoglycemia rates were lower with IDegLira versus basal insulin and higher versus unchanged GLP-1RA (estimated rate ratios, 0.5 [0.2; 1.6]<sub>95% CI</sub> [ P = .242]; 0.3 [0.1; 0.5]<sub>95% CI</sub> [ P<.001], and 11.8 [3.3; 42.8]<sub>95% CI</sub> [ P<.001] for DUAL II, V, and III, respectively).
|
30383495 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1RAs may be considered in combination with other glucose-lowering medications because of their ability to lower glucose in a glucose-dependent manner, lowering their risk for hypoglycemia, while improving some cardiorenal risk factors.
|
31318152 |
2019 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
SGLT-2i plus GLP-1RA therapy was generally well tolerated, with a low risk of hypoglycemia and no unexpected findings.
|
31580737 |
2019 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
GLP-1RAs are generally well tolerated, with gastrointestinal and injection-site reactions being the most troublesome drug-related adverse events, and are associated with a very low intrinsic risk of hypoglycaemia.
|
31317516 |
2019 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A short-acting GLP-1RA plus basal insulin is an alternative to premixed insulin, resulting in better efficacy and a lower risk of hypoglycemia and weight gain.
|
30859500 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) exert potent glucose-lowering effects without increasing risks for hypoglycemia and weight gain.
|
30860874 |
2019 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The risk of hypoglycemia was increased with TZD or GLP-1RA.
|
29511288 |
2018 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Notably, the combination of SU plus glucagon-like peptide-1 receptor agonist (GLP-1RA) was associated with the most significant increase in the risk of hypoglycemia.
|
30148851 |
2018 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium glucose cotransporter 2 inhibitors (SGLT2i) are of particular interest in type 2 diabetes treatment strategies, due to their efficacy in reducing HbA1c with a low risk of hypoglycaemia, to their positive effects on body weight and blood pressure and in light of their effects on cardiovascular risk and on nephroprotection emerged from the most recent cardiovascular outcome trials.
|
29334278 |
2018 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Results for third-line agents added to metformin and TZDs were comparable, showing similar HbA1c reduction and risk of hypoglycaemia between SGLT-2 inhibitors and GLP-1RAs, and a slightly greater reduction in body weight with SGLT-2 inhibitors vs GLP-1RAs.
|
29205774 |
2018 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.
|
29272081 |
2017 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated the effect of the GLP-1RA liraglutide on counterregulatory responses and GE rate during hypoglycaemia in persons with T1D.
|
27868372 |
2017 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In a study comparing the addition of exenatide QW and pioglitazone with the addition of basal-bolus insulin in 101 people receiving sulfonylureas and metformin with baseline HbA1c >10%, HbA1c fell from >11% by >4% compared with <4%, respectively, and the GLP-1RA plus thiazolidinedione treatment was associated with less weight gain and hypoglycemia.What can we conclude?
|
28589542 |
2017 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Expert opinion: IDegLira provides superior glycaemic control and mitigates the primary adverse effects associated with insulin therapy (weight gain and hypoglycaemia) and GLP-1RAs (gastrointestinal side effects) with no indication of additive effects.
|
28150516 |
2017 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The risk of hypoglycemia with GLP-1RAs is minimal; however, GLP-1RAs are associated with gastrointestinal adverse events and raise concerns regarding pancreatitis.
|
28526416 |
2017 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
As its glucose-lowering action is glucose dependent, a GLP-1 receptor agonist (GLP-1RA) achieves these benefits with a lower risk of hypoglycemia compared with other diabetes therapies.
|
28721686 |
2017 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
When all GLP-1RAs were compared with each other, no clinically meaningful differences were observed in weight loss, blood pressure reduction or hypoglycaemia risk.
|
27981757 |
2017 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, I provide a clinical update of glucagon-like peptide-1 receptor agonists (GLP-1RAs), a class of incretin-based, injectable antidiabetes therapies which improve fasting and postprandial blood glucose control through glucose-dependent pancreatic islet cell hormone secretion without significant risks for hypoglycemia.
|
28942790 |
2017 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Besides improving glycemic control, the GLP-1RAs have other beneficial effects such as weight loss and a low risk of hypoglycemia.
|
28102093 |
2017 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1As decreased risks of all-cause and CV mortality and severe hypoglycemia, whereas DPP-4Is had no effect on CV outcomes but increased risks in acute pancreatitis and hypoglycemia.
|
28249585 |
2017 |